Rash development has been associated with EGFR-TKI efficacy in NSCLC, and a meta-analysis previously showed that a skin rash was an independent predictive factor for progression and survival in EGFR TKI-treated NSCLC patients (10). The gene discussed is EGFR; the disease is exanthem.